Get the Stockscreener App
45.09
0.60%
0.27
After Hours:
45.09
Avidity Biosciences Inc stock is traded at $45.09, with a volume of 759.92K.
It is up +0.60% in the last 24 hours and down -4.67% over the past month.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
See More
Previous Close:
$44.82
Open:
$44.82
24h Volume:
759.92K
Relative Volume:
0.60
Market Cap:
$5.30B
Revenue:
$10.60M
Net Income/Loss:
$-252.45M
P/E Ratio:
-14.55
EPS:
-3.1
Net Cash Flow:
$-158.91M
1W Performance:
+1.17%
1M Performance:
-4.67%
6M Performance:
+70.47%
1Y Performance:
+724.31%
1-Day Range:
$43.39
$45.43
1-Week Range:
$41.12
$45.59
52-Week Range:
$5.15
$50.78
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Avidity Biosciences (NASDAQ:RNA) Trading 6.5% HigherShould You Buy? - MarketBeat
Vanguard Group Inc's Strategic Acquisition in Avidity Biosciences Inc - GuruFocus.com
Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024 - PR Newswire
Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Avidity Biosciences advances FSHD therapy trial By Investing.com - Investing.com Canada
Avidity Biosciences target held at $59 by Goldman Sachs - Investing.com Canada
Chardan Capital Raises Avidity Biosciences (NASDAQ:RNA) Price Target to $65.00 - MarketBeat
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Faciosca - StreetInsider.com
Avidity Biosciences advances FSHD therapy trial - Investing.com
Avidity Biosciences Pursues Potential Accelerated Approval Path with Initiation of Biomarker Cohort in FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax/AOC 1020) in People Living with Facioscapulohumeral Muscular Dystrophy – Company Announce - Financial Times
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Shares Purchased by China Universal Asset Management Co. Ltd. - MarketBeat
Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors - StockTitan
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 5,000 Shares of Stock - MarketBeat
Avidity Biosciences director Levin sells $233k in stock By Investing.com - Investing.com UK
In-Depth Examination Of 10 Analyst Recommendations For Avidity Biosciences - Benzinga
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Financial Times
TD Cowen Boosts Avidity Biosciences (NASDAQ:RNA) Price Target to $78.00 - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Trading Down 5.2%What's Next? - MarketBeat
Moss Adams Wealth Advisors LLC Reduces Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells 25,000 Shares of Stock - MarketBeat
Avidity Biosciences chief HR officer McCarthy sells $1.21m in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief HR officer McCarthy sells $1.21m in stock - Investing.com
Avidity Biosciences Announces Expansion of Cardiovascular Collab - GuruFocus.com
Avidity Biosciences (NASDAQ:RNA) Hits New 1-Year HighWhat's Next? - MarketBeat
Avidity Biosciences stock soars to all-time high of $49.47 - Investing.com India
Avidity Biosciences stock soars to all-time high of $49.47 By Investing.com - Investing.com UK
Avidity Biosciences, Inc. (NASDAQ:RNA) Sees Large Increase in Short Interest - MarketBeat
SG Americas Securities LLC Has $582,000 Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC - GuruFocus.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Stake Reduced by Millennium Management LLC - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Stock Price Down 5.5% on Insider Selling - MarketBeat
Avidity Biosciences director sells $1.35m in company stock By Investing.com - Investing.com South Africa
Avidity Biosciences director sells $1.35m in company stock - Investing.com India
Insider Selling: Avidity Biosciences, Inc. (NASDAQ:RNA) Director Sells 30,000 Shares of Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Stock Price Up 4.8%Should You Buy? - MarketBeat
Why Avidity Biosciences Zoomed to a 12% Gain This Week - MSN
Goldman Sachs Group (GS-N) QuotePress Release - The Globe and Mail
Avidity Biosciences shares buoyed by FDA lift on clinical hold - Investing.com Canada
FDA lifts hold on Avidity’s delpacibart etedesiran trial - The Pharma Letter
FDA lifts hold on Avidity Biosciences' DM1 drug trial By Investing.com - Investing.com South Africa
The Manufacturers Life Insurance Company Raises Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences' drug cleared by FDA By Investing.com - Investing.com South Africa
Avidity Biosciences' drug cleared by FDA - Investing.com
Avidity Biosciences: Good Prospects, But We Are A Little Late (RNA) - Seeking Alpha
Goldman Sachs maintains Buy rating on Avidity Biosciences shares By Investing.com - Investing.com UK
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001) - GuruFocus.com
FDA lifts hold on Avidity Biosciences' DM1 drug trial - Investing.com
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| LEVIN ARTHUR A | Director |
Oct 21 '24 |
Sale |
46.63 |
5,000 |
233,168 |
14,830 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):